Matching Adjusted Indirect Comparisons of Personalized Prophylaxis with Simoctocog Alfa Versus Efmoroctocog Alfa, Damoctocog Alfa Pegol and Rurioctocog Alfa Pegol in Patients with Hemophilia a

被引：0
|
作者：
Kessler, Craig M. [1 ]
Tiede, Andreas [2 ]
机构：
[1] Georgetown Univ, Sch Med, Washington, DC USA
[2] Hannover Med Sch, Clin Haematol Haemostaseol Oncol & Stem Cell Tran, Hannover, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162205
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2755 / 2756
页数：2
相关论文
共 50 条
  • [41] Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method
    Kessler, Craig M.
    Corrales-Medina, Fernando F.
    Mannucci, Pier Mannuccio
    Jimenez-Yuste, Victor
    Tarantino, Michael D.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (05) : 757 - 767
  • [42] Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study
    Holme, Pal Andre
    Poulsen, Lone Hvitfeldt
    Tueckmantel, Claudia
    Enriquez, Monika Maas
    Roman, Maria Teresa Alvarez
    De Cristofaro, Raimondo
    HAEMOPHILIA, 2024, 30 (02) : 388 - 394
  • [43] Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan
    Fujii, Teruhisa
    Kidoguchi, Yuko
    Takahashi, Noriko
    Yu, Eric
    Ainiwaer, Dilinuer
    Byrne, Aidan
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 218 - 225
  • [44] IMMUNOGENICITY PROFILE OF RURIOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH SEVERE CONGENITAL HEMOPHILIA A: FINDINGS FROM 6 CLINICAL TRIALS
    Horling, F. M.
    Engl, W.
    Reipert, B. M.
    Tangada, S.
    HAEMOPHILIA, 2020, 26 : 123 - 124
  • [45] REAL-WORLD EFFECTIVENESS OF DAMOCTOCOG ALFA PEGOL IN MILD AND MODERATE HEMOPHILIA A PATIENTS AGED 12 YEARS AND OLDER IN THE ATHNDATASET
    Chandler, Martin
    Charafi, Lena
    Moulton, Thomas
    Recht, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E18 - E19
  • [46] ALFA PROTECT: A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED CHILDREN AGED 7<12 YEARS WITH SEVERE HEMOPHILIA A
    Ducore, Jonathan
    Enriquez, Monika Mass
    Tueckmantel, Claudia
    Simpson, Mindy
    Ahuja, Sanjay
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E31 - E31
  • [47] PHASE 3B, OPEN-LABEL, MULTICENTER, CONTINUATION STUDY OF RURIOCTOCOG ALFA PEGOL FOR PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
    Alvarez Roman, M. T.
    Mullins, E.
    Chowdary, P.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMATOLOGICA, 2019, 104 : 112 - 113
  • [48] SAFETY AND EFFICACY OF DAMOCTOCOG ALFA PEGOL PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: FINAL RESULTS OF A POST-MARKETING, INTERVENTIONAL STUDY
    Holme, P. A.
    Poulsen, L. H.
    Tueckmantel, C.
    Enriquez, M. Maas
    Alvarez Roman, T.
    De Cristofaro, R.
    HAEMOPHILIA, 2023, 29 : 82 - 82
  • [49] SAFETY AND EFFICACY OF DAMOCTOCOG ALFA PEGOL PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: INTERIM RESULTS OF A POST-MARKETING, INTERVENTIONAL STUDY
    Holme, P. A.
    Poulsen, L. H.
    Tueckmantel, C.
    Maas Enriquez, M.
    Alvarez Roman, M. T.
    De Cristofaro, R.
    HAEMOPHILIA, 2022, 28 : 88 - 88
  • [50] Excellent Clinical and Pharmacokinetic Real-World Experience after Switching to Rurioctocog ALFA Pegol
    Hidalgo, Olga Benitez
    Jaime, Francisco Jose Lopez
    Garcia, Maria Fernanda Martinez
    Gimenez, Juan Carlos Juarez
    Martinez, Eva Alvarez
    Suito, Milagros
    Bosch, Francesc
    Mesa, Mercedes Gironella
    BLOOD, 2020, 136
12345